Display options
Cite
Li Y, Kobayashi K, Mona MM, et al. Immunogenic FEAT protein circulates in the bloodstream of cancer patients. J Transl Med. 2016;14(1):275doi: 10.1186/s12967-016-1034-2.
Li, Y., Kobayashi, K., Mona, M. M., Satomi, C., Okano, S., Inoue, H., Tani, K., & Takahashi, A. (2016). Immunogenic FEAT protein circulates in the bloodstream of cancer patients. Journal of translational medicine, 14(1), 275. https://doi.org/10.1186/s12967-016-1034-2
Li, Yan, et al. "Immunogenic FEAT protein circulates in the bloodstream of cancer patients." Journal of translational medicine vol. 14,1 (2016): 275. doi: https://doi.org/10.1186/s12967-016-1034-2
Li Y, Kobayashi K, Mona MM, Satomi C, Okano S, Inoue H, Tani K, Takahashi A. Immunogenic FEAT protein circulates in the bloodstream of cancer patients. J Transl Med. 2016 Sep 22;14(1):275. doi: 10.1186/s12967-016-1034-2. PMID: 27659353; PMCID: PMC5034574.
Copy Download .nbib Format: NLM
Share it on

J Transl Med. 2016 Sep 22;14(1):275. doi: 10.1186/s12967-016-1034-2.

Immunogenic FEAT protein circulates in the bloodstream of cancer patients.

Journal of translational medicine

Yan Li, Kyosuke Kobayashi, Marwa M Mona, Chikako Satomi, Shinji Okano, Hiroyuki Inoue, Kenzaburo Tani, Atsushi Takahashi

Affiliations

  1. Division of Molecular and Clinical Genetics, Kyushu University, Fukuoka, Japan.
  2. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan.
  3. Department of Medical Biochemistry, Faculty of Medicine, Tanta University, Tanta, Egypt.
  4. Division of Translational Cancer Research, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan.
  5. Department of Innovative Applied Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  6. Division of ALA Advanced Medical Research, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  7. Division of Molecular and Clinical Genetics, Kyushu University, Fukuoka, Japan. [email protected].
  8. Division of Translational Cancer Research, Medical Institute of Bioregulation, Kyushu University, Fukuoka, Japan. [email protected].
  9. Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, 54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan. [email protected].

PMID: 27659353 PMCID: PMC5034574 DOI: 10.1186/s12967-016-1034-2

Abstract

BACKGROUND: FEAT is an intracellular protein that potently drives tumorigenesis in vivo. It is only weakly expressed in normal human tissues, including the testis. In contrast, FEAT is aberrantly upregulated in most human cancers. The present study was designed to investigate whether FEAT is applicable to tumor immunotherapy and whether FEAT is discernible in the bloodstream as a molecular biomarker of human cancers.

METHODS: Two mouse FEAT peptides with predicted affinities for major histocompatibility complex H-2Kb and H-2Db were injected subcutaneously into C57BL/6 mice before subcutaneous transplantation of isogenic B16-F10 melanoma cells. Intracellular localization of FEAT was determined by immunogold electron microscopy. Immunoprecipitation was performed to determine whether FEAT was present in blood from cancer patients. A sandwich enzyme-linked immunosorbent assay was used to measure FEAT concentrations in plasma from 30 cancer patients and eight healthy volunteers.

RESULTS: The vaccination experiments demonstrated that FEAT was immunogenic, and that immune responses against FEAT were induced without deleterious side effects in mice. Electron microscopy revealed localization of FEAT in the cytoplasm, mitochondria, and nucleus. Immunoprecipitation identified FEAT in the blood plasma from cancer patients, while FEAT was not detected in plasma exosomes. Plasma FEAT levels were significantly higher in the presence of cancers.

CONCLUSIONS: These findings suggest that FEAT is a candidate for applications in early diagnosis and prevention of some cancers.

Keywords: Cancer prevention; Cancer screening; ELISA; FEAT; Immunotherapy; METTL13; Tumor marker

References

  1. Cell. 2015 Apr 9;161(2):205-14 - PubMed
  2. Immunol Rev. 2008 Apr;222:316-27 - PubMed
  3. Int J Cancer. 2002 Sep 1;101(1):1-6 - PubMed
  4. Curr Opin Genet Dev. 2015 Feb;30:7-16 - PubMed
  5. Cancer Res. 2003 Apr 15;63(8):1727-30 - PubMed
  6. J Clin Invest. 2015 Sep;125(9):3401-12 - PubMed
  7. Clin Immunol. 2016 May;166-167:48-58 - PubMed
  8. BMC Genomics. 2011 Jul 04;12:340 - PubMed
  9. J Surg Oncol. 2014 Jun;109(8):830-5 - PubMed
  10. Sci Transl Med. 2012 Mar 28;4(127):127rv4 - PubMed
  11. Nat Rev Mol Cell Biol. 2013 Nov;14(11):727-36 - PubMed
  12. Lancet Oncol. 2014 Oct;15(11):e484-92 - PubMed
  13. Cancer. 1988 Oct 15;62(8 Suppl):1676-9 - PubMed
  14. Science. 2015 Jan 2;347(6217):78-81 - PubMed
  15. Nat Rev Cancer. 2013 Oct;13(10 ):739-52 - PubMed
  16. Clin Vaccine Immunol. 2011 Jan;18(1):23-34 - PubMed
  17. JAMA. 2015 Oct 20;314(15):1615-34 - PubMed
  18. Sci Rep. 2011;1:15 - PubMed
  19. Nat Rev Cancer. 2012 Apr 12;12(5):368-71 - PubMed
  20. Cancer Biol Med. 2015 Sep;12(3):201-8 - PubMed
  21. Immunogenetics. 1995;41(4):178-228 - PubMed
  22. Curr Opin Immunol. 2013 Apr;25(2):284-90 - PubMed
  23. Cancer Sci. 2016 Apr;107(4):385-90 - PubMed
  24. Nat Med. 2004 Sep;10(9):909-15 - PubMed
  25. Mol Oncol. 2015 Dec;9(10):2054-62 - PubMed
  26. Nature. 2016 Jan 7;529(7584):43-7 - PubMed
  27. Nature. 2013 Apr 25;496(7446):445-55 - PubMed
  28. Nat Med. 2013 Apr;19(4):465-72 - PubMed
  29. Immunity. 2013 Mar 21;38(3):414-23 - PubMed
  30. Cancer. 2010 May 1;116(9):2071-80 - PubMed
  31. Trends Cell Biol. 2015 Jul;25(7):398-407 - PubMed
  32. Nature. 2013 Sep 19;501(7467):355-64 - PubMed
  33. Nat Rev Mol Cell Biol. 2009 Feb;10(2):148-55 - PubMed
  34. J Immunol. 1994 Jan 1;152(1):163-75 - PubMed
  35. Science. 2003 Oct 24;302(5645):643-6 - PubMed
  36. Sci Rep. 2016 Jan 14;6:19261 - PubMed
  37. Nat Rev Cancer. 2005 Aug;5(8):615-25 - PubMed
  38. PLoS One. 2007 Aug 29;2(8):e796 - PubMed
  39. Nat Rev Immunol. 2009 Aug;9(8):581-93 - PubMed
  40. Nature. 2011 Dec 21;480(7378):480-9 - PubMed
  41. Nat Rev Genet. 2014 Sep;15(9):585-98 - PubMed
  42. Nature. 2015 Oct 29;526(7575):660-5 - PubMed
  43. BMC Cancer. 2015 Jun 02;15:448 - PubMed
  44. Science. 2013 Mar 29;339(6127):1546-58 - PubMed
  45. Curr Opin Cell Biol. 2009 Aug;21(4):575-81 - PubMed
  46. PLoS One. 2013 Jul 02;8(7):e67554 - PubMed
  47. Hum Pathol. 2016 Mar;49:114-23 - PubMed
  48. N Engl J Med. 2008 Jun 19;358(25):2704-15 - PubMed

Publication Types